Stay updated with breaking news from Nasdaq Beam. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) posted its earnings results on Wednesday. The company reported ($1.22) earnings per share for the quarter, topping the consensus estimate of ($1.33) by $0.11, Briefing.com reports. Beam Therapeutics had a negative net margin of 408.13% and a negative return on equity of 43.32%. The business had revenue of […]
Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have been given a consensus rating of “Hold” by the eleven brokerages that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price […]
Cantor Fitzgerald lowered shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from an overweight rating to a neutral rating in a research report sent to investors on Friday, Briefing.com reports. Cantor Fitzgerald also issued estimates for Beam Therapeutics’ FY2024 earnings at ($4.85) EPS. Several other equities research analysts have also weighed in on BEAM. SVB […]
Beam Therapeutics (NASDAQ:BEAM – Free Report) had its price objective cut by Cantor Fitzgerald from $56.00 to $32.00 in a report released on Tuesday morning, Benzinga reports. They currently have an overweight rating on the stock. Other equities analysts also recently issued reports about the company. Barclays reduced their price objective on Beam Therapeutics from […]
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) was downgraded by equities research analysts at SVB Leerink from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday, Briefing.com reports. They presently have a $20.00 target price on the stock, down from their previous target price of […]